BSE filing, NSE: SUNPHARMA. Summary written from the filing by ALFA Finder's alert engine.
Sun Pharmaceutical Industries Ltd: key numbers
- Share price
- ₹1,757.50
- Market cap
- ₹4,21,683 Cr
- Revenue (annual)
- ₹58,462 Cr
- Net profit (annual)
- ₹11,479 Cr
- P/E (TTM)
- 34.9×Sector 46.1×
- Promoter holding
- 52.68%-1.80% QoQ
- FII holding
- 14.36%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Sun Pharmaceutical Industries Ltd
All →Sun Pharmaceutical Industries Debt & Borrowing: ₹7,816 Cr
Sun Pharma completed allotment of ₹7,816 crore NCDs via private placement, exercising its greenshoe option of ₹816 crore. The unsecured debentures carry 8.05–8.20% coupons maturing October 2031.
- Value
- ₹7,816 Cr
- Execution
- 5 years and 1 day (26 Oct 2026 to 27 Oct 2031)
Sun Pharmaceutical Industries Business Update
Sun Pharma's drug UNLOXCYT received Category 2A preferred designation in updated NCCN guidelines for treating locally advanced cutaneous squamous cell carcinoma.
Sun Pharmaceutical Industries Other Announcement
Sun Pharmaceutical Industries submitted the quarterly confirmation certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, as received from their RTA.
Sun Pharmaceutical Industries Management Change
Sun Pharmaceutical Industries announced the resignation of Independent Director Gautam Doshi due to personal reasons.
Sun Pharmaceutical Industries Debt & Borrowing: ₹10,000 Cr
Sun Pharma's board approved issuing unsecured Non-Convertible Debentures up to ₹10,000 Crore. Additionally, Independent Director Mr. Gautam Doshi resigned from the company's board.
- Value
- ₹10,000 Cr
Sun Pharmaceutical Industries Board Meeting Date
Sun Pharmaceutical Industries Limited will hold a board meeting on October 12, 2026, to consider a proposed debt issue for fund raising.
Other credit rating announcements
All →GSPL Transmission Credit Rating
CARE Ratings assigned GSPL Transmission a CARE AA+ rating on bank facilities with a stable outlook. The rating cites nil debt and strong liquidity.
Meghmani Organics Credit Rating
India Ratings assigned Meghmani Organics' bank loan facilities of INR 11,000 million a rating of IND A/Stable/IND A1. The filing encloses the rating letter and a facilities breakup.
JSW Cement Credit Rating
CRISIL reaffirmed JSW Cement's long-term rating at AA-/Stable and its short-term ratings at A1+. No new borrowing or fund raise is announced.
Tejas Networks Credit Rating
ICRA reaffirmed Tejas Networks' [ICRA]A+(Stable) long-term rating and [ICRA]A1+ short-term rating. The rating covers Rs.6,000 Crore of credit facilities and a Rs.500 Crore CP programme.
HDB Financial Services Credit Rating
CARE Ratings reaffirmed HDB Financial Services' AAA rating with Stable outlook across its debt instruments. Its A1+ short-term rating was also reaffirmed.
Asian Energy Services Credit Rating
Asian Energy Services Limited disclosed that CRISIL maintained its 'Watch Developing' rating on INR 317.5 Crore of bank facilities. The watch continues pending final Ministry of Petroleum approval for the merger of its parent, Oilmax Energy.